Avenue therapeutics reports third quarter 2024 financial results and recent corporate highlights

- topline data in phase 1b/2a clinical trial of aj201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 - topline data in phase 1b/2a clinical trial of aj201 for spinal and bulbar muscular atrophy anticipated around year-end 2024
ATXI Ratings Summary
ATXI Quant Ranking